Victor Chow, MD, senior hematology-oncology fellow, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses a retrospective study assessing outcomes of patients with large B-cell lymphomas and progressive disease following CD19-Specific CAR T-cell therapy during the 2018 ASH Annual Meeting.

Related Content

Careful Data Review Recommended for Upfront Treatment Selection in iNHL

February 29, 2020 11:30pm

By Jason M. Broderick

News Therapies Emerge to Combat Aggressive Lymphomas

February 29, 2020 02:18am

By Sameer Desai, MD

Early AE Management With Corticosteroids Has Potential to Reduce Rates and Severity of Toxicity With Axi-Cel

February 22, 2020 06:30pm

By Audrey Sternberg

Across Subtypes of B-cell NHL, REGN1979 Produces Promising Responses

December 11, 2019 12:01am

By Wayne Kuznar